Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal

Abstract

Gordon et al. conclude that risankizumab has a higher efficacy than placebo and ustekinumab in the treatment of moderate-to-severe chronic plaque psoriasis, and that the adverse-event profiles were similar across all treatment groups.